Renowned forensic physical anthropologist Dr. T. Dale Stewart traveled extensively to countries all over the world. The reasons for his journeys were manifold. He did fieldwork, took part in congresses, visited scientific institutions, and lectured by invitation at various universities. This paper deals with his journeys in general and with his four visits to Czechoslovakia in particular. Three of them were undertaken in connection with scientific congresses dedicated to Dr. Ales Hrdlicka. Dr. Stewart, as Hrdlicka's successor in the Smithsonian Institution, always chose an appropriate topic for his lecture. His visits to Hrdlicka's native country and town contributed to better mutual understanding and exchange of ideas between physical anthropologists and anatomists from both countries, the USA and Czechoslovakia (the today separate Czech and Slovak Republics).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Genetic diversity of United States Rambouillet, Katahdin and Dorper sheep.
Genet Sel Evol
July 2024
Department of Animal, Veterinary and Food Science, University of Idaho, Moscow, ID, USA.
Background: Managing genetic diversity is critically important for maintaining species fitness. Excessive homozygosity caused by the loss of genetic diversity can have detrimental effects on the reproduction and production performance of a breed. Analysis of genetic diversity can facilitate the identification of signatures of selection which may contribute to the specific characteristics regarding the health, production and physical appearance of a breed or population.
View Article and Find Full Text PDFStratified analyses refine association between TLR7 rare variants and severe COVID-19.
HGG Adv
October 2024
Institute of Human Genetics, University of Bonn School of Medicine and University Hospital Bonn, Bonn, Germany. Electronic address:
Despite extensive global research into genetic predisposition for severe COVID-19, knowledge on the role of rare host genetic variants and their relation to other risk factors remains limited. Here, 52 genes with prior etiological evidence were sequenced in 1,772 severe COVID-19 cases and 5,347 population-based controls from Spain/Italy. Rare deleterious TLR7 variants were present in 2.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to create a new prognostic model to estimate the risk of pulmonary complications after elective surgery, which is the leading cause of post-surgery death.
- Data from a large international cohort of over 86,000 patients was used, applying machine learning techniques to identify risk factors for complications like pneumonia and respiratory distress.
- The model, named the GSU-Pulmonary Score, was validated with additional cohorts and is available as an online tool to assist in patient care and resource management, especially important during pandemic recovery.
Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials.
Mov Disord
August 2024
Department of Neurology, University Hospital, LMU Munich, Munich, Germany.
Article Synopsis
- - The study investigates various MRI measures as biomarkers for tracking brain atrophy progression in patients with progressive supranuclear palsy (PSP), focusing on comparing different staging systems and assessing their effectiveness for clinical trials.
- - 508 participants were analyzed, including PSP patients and healthy controls, with specific attention given to the brainstem and midbrain volumes, which showed the most significant changes over one year.
- - Results suggest that automated atlas-based volumetry is more sensitive and requires smaller sample sizes than other methods for detecting atrophy progression in PSP, potentially aiding in the evaluation of treatment efficacy in clinical trials.
A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome.
Blood
July 2024
Centre de Référence des Neutropénies Chroniques, Assistance Publique-Hôpitaux de Paris Sorbonne Université-Hôpital d'Enfants Armand-Trousseau, Paris, France.
Article Synopsis
- A phase 3 trial was conducted to evaluate the efficacy and safety of mavorixafor, an oral medication, in individuals with WHIM syndrome, a rare immunodeficiency disorder caused by genetic mutations.
- Participants were randomly assigned to receive either mavorixafor or a placebo for 52 weeks, with the study focusing on the time above certain white blood cell counts as the primary endpoint.
- Results showed mavorixafor significantly increased white blood cell counts, reduced infection rates and severity, and was well tolerated without serious adverse events occurring during the study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!